Talc Litigation in The UK: Cost and Reputational Stakes for Insurers

The recent filing of group litigation in the High Court of England and Wales against Johnson & Johnson (J&J) and Kenvue Limited is a significant development for the insurance market. In September 2024, KP Law, who are acting for the claimant group, sent a pre-action letter to J&J evincing their intention to commence proceedings in the UK. Just over a year later, their intention was realised, with the claim being filed in the High Court in October 2025. Whilst the particulars of claim are not yet publicly available, detailed reports have been published by the BBC and The Guardian extrapolating its key elements.

The claim is brought on behalf of approximately 3,000 UK individuals and concerns alleged exposures to talk-based personal products said to contain, or be contaminated by, asbestos. The period of exposure spans from 1965 to 2023, when the UK discontinued the sale of talc-based baby powders. While similar claims have been brought in other jurisdictions, this claim is the first of its kind to be brought on UK soil. The commencement of UK proceedings sharpens key liability, coverage, and reputational challenges that insurers will need to manage as the action progresses.

Claimants plead negligence, breach of statutory duty under UK product safety regimes, and strict liability under the Consumer Protection Act 1987 (CPA 1987). It is alleged that the defendants failed to design and test products properly, ensure quality control, warn of asbestos risks in mined talc and conduct adequate risk assessments or disclosures. Central assertions include that talcum powder contained fibrous talc, tremolite, and actinolite (classified as asbestos) and that defendants knew or should have known of contamination risks and links to certain cancers since at least the 1960s. Media reports note allegations of no warnings despite knowledge and a marketing message of “purity and safety,” which the defendants dispute, citing regulatory compliance and denying asbestos presence or carcinogenicity.

Causation will play a key role in proceedings. Claimants must prove general causation (that asbestos-contaminated talc can cause the alleged cancers, often ovarian cancer or mesothelioma) and specific causation (that a claimant’s risk of cancer was materially increased due to the defendant’s breach of duty). It is anticipated that the litigation process will involve extensive disputes over epidemiology linking talc and ovarian cancer and the existence, levels and routes of asbestos exposure in consumer products. Defendants will challenge contamination evidence and propose alternative causes, including genetics and other environmental exposures. For mesothelioma, UK case law on material contribution and evidential sufficiency will be crucial, and any “any exposure” asbestos logic will be scrutinised. Expert evidence across mineralogy, industrial hygiene, and oncology will be central to both liability and coverage.

Personal injury claims generally face a three-year limitation from injury or the claimant’s date of knowledge of the injury and its cause, subject to the court’s discretion under s.33 Limitation Act 1980 (LA 1980). Liability claims brought under the CPA have a ten-year long stop from the date the product entered circulation. Defendants may argue earlier “date of knowledge,” pointing to publicity and warnings; claimants will, when appropriate, seek the judicial discretionary extension due to the latency of the disease and evolving science. For deceased claimants, dependency claims under the Fatal Accidents Act 1976 have a three-year limit from death or the dependent’s date of knowledge, while estate claims under the Law Reform (Miscellaneous Provisions) Act 1934 track the deceased’s original accrual. For insurers, limitation can materially narrow exposure, but s.33 discretion and the sensitivity of fatal or serious illness claims add uncertainty that should be reflected in reserves.

UK product and public liability policies commonly contain broad asbestos exclusions, often expressed to exclude claims “arising out of,” “caused by or attributable to” asbestos exposure or fear of exposure, or “directly or indirectly related to” asbestos, including its handling or presence. Under English law, broad phrasing is generally interpreted widely, giving insurers a strong basis to decline indemnity and defence costs where claims depend on asbestos contamination.

Narrower wording—such as exclusions only for claims “caused by” asbestos—invites closer proximate cause analysis and more nuanced results, particularly if claimants frame allegations on a talc-only theory (for example, ovarian cancer causation independent of asbestos). Early indications suggest the UK claims are pleaded as asbestos-based, favouring the application of exclusions; however, if pleadings pivot to talc-only causation, the absence of an asbestos trigger complicates coverage and may reintroduce defence cost exposure even if indemnity is ultimately challenged.

Large-scale group litigation typically brings heavy disclosure, multiple expert disciplines, and extensive case management, all driving defence costs. Where asbestos exclusions apply, some insurers may decline defence outright; others may reserve rights while pleadings, causation theories, and evidence mature. Even with robust exclusions, insurers should consider scenarios where parts of claims fall outside exclusionary scope due to pleading strategy, judicial causation analysis, or shifts in scientific consensus. Aggregation, trigger, and policy period questions will complicate indemnity, given alleged exposures across decades, multiple programs and evolving products and supply chains. Reserves should anticipate mixed results, including partial recoveries, adverse costs and settlements aimed at reducing uncertainty.

The products at issue were marketed for family use, and allegations of knowledge and inadequate warnings will attract public attention. Coverage positions, especially any perceived reluctance to defend, will be looked at closely by stakeholders focused on consumer protection and corporate responsibility. Insurers will need to maintain underwriting discipline and adhere to policy language to avoid moral hazard or retrospective dilution of exclusions. Clear, principled communication with insureds and brokers, grounded in law and evidence, can mitigate reputational risk. Claims handling should be sensitive to the human context of serious or fatal disease, balancing legal rigour with empathy to avoid amplifying reputational harm.

This coordinated, multi-jurisdictional litigation suggests sustained claim activity and evolving liability and causation theories. Insurers should reassess underwriting for products involving mined minerals and complex supply chains; tighten wording on contamination, latent disease, and “indirect” exposure; and stress-test portfolio vulnerability to long-tail consumer product claims. Claims and legal teams should track the UK proceedings for judicial signals on causation thresholds, limitation discretion, and exclusion interpretation. Where coverage may attach, through gaps in exclusions, legacy policies, or talc-only pleadings, early focus on defence strategy, expert selection, and settlement can mitigate cost exposure. A coordinated market approach may be prudent where exposures are spread across multiple insurers.

The UK talc group litigation raises difficult coverage questions. Broad asbestos exclusions may significantly curb indemnity and defence for asbestos-based claims, but litigation complexity and potential talc-only theories demand careful, claim-by-claim analysis. Cost risk stems from prolonged, expert-heavy proceedings and contested causation; reputational risk flows from the consumer-facing nature of the products and the sensitivity of the allegations. Insurers should combine coverage evaluation with measured communication and prudent reserving, preparing for outcomes shaped by law, science, and public perception.